PMID- 34867326
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211207
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Comparison of Traditional Chinese Medicine in the Long-Term Secondary Prevention 
      for Patients with Ischemic Stroke: A Systematical Analysis.
PG  - 722975
LID - 10.3389/fphar.2021.722975 [doi]
LID - 722975
AB  - Background: Keeping in view the high recurrence rate and risk of ischemic stroke, 
      combinatorial therapy involving traditional Chinese medicine (TCM) with 
      conventional Western medicine (WM) is receiving wider scientific attention. Thus, 
      a systematical analysis was made to explore the efficacy of TCM+WM in the 
      long-term secondary prevention for patients with ischemic stroke. Methods: 
      Qualified inclusion and exclusion criteria were set up beforehand, and two 
      researchers independently read the articles, extracted data, and evaluated the 
      quality of included articles according to Cochrane Reviewer's Handbook 5.1 
      method. For the sake of comprehensive data acquisition, seven databases from the 
      time of their establishment to May 5, 2021, have been searched completely. 
      Additionally, pairwise meta-analysis was made to compare TCM+WM vs. WM, and 
      network meta-analysis was conducted by frequentist random effects models for the 
      comparison of different kinds of TCM+WM via indirect evidence. The primary 
      outcomes defined were recurrent stroke and NIHSS. Secondary outcomes were 
      fibrinogen (Fib) fasting blood glucose (FBG), triglycerides (TG), and total 
      cholesterol (TC). Safety outcomes were outlined as all-cause mortality and 
      adverse events (AEs). Furthermore, Stata16.0 software was used to accomplish the 
      systematical analysis and cluster analysis. Results: In total, 47 qualified 
      randomized controlled trials (RCTs) including 10,732 patients were taken into 
      consideration. Seven traditional Chinese medicines included in the study are 
      Naoxintong capsule (NXT), Tongxinluo capsule (TXL), Buyang Huanwu decoction 
      (BYHW), Naomaitai capsule (NMT), Dengzhan Shengmai capsule (DZSM), Naoshuantong 
      capsule (NST), and Maixuekang capsule (MXK). With respect to their primary 
      outcomes, all kinds of TCM+WM were significantly more effective than WM (e.g., 
      NXT in recurrent stroke (OR=0.54, P<0.01), TXL in NIHSS (WM=-1.4, P<0.01)). 
      Additionally, the outcomes of cluster analysis indicated that MXK+WM and NST+WM 
      had relatively good preventive effects for recurrent stroke, NIHSS, and all-cause 
      mortality. There was no significant difference in the comparisons of AEs; 
      however, this may arise from the lack of sufficient data. Conclusion: According 
      to our systematical analysis, MXK+WM and NST+WM had relatively good secondary 
      prevention effects for patients with ischemic stroke regarding recurrent stroke, 
      NIHSS, and all-cause mortality. Nevertheless, better, high-quality, large-sample 
      randomized clinical trials (RCTs) are required to verify our conclusions in the 
      future. Systematic Review Registration: 
      [https://inplasy.com/inplasy-2021-5-0036/], identifier [INPLASY202150036].
CI  - Copyright (c) 2021 Li, Zhao, Zhang, Wan, He, Li, Yu and Jin.
FAU - Li, Jiali
AU  - Li J
AD  - The Second School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Zhao, Xixi
AU  - Zhao X
AD  - School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Zhang, Yangyang
AU  - Zhang Y
AD  - School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Wan, Haitong
AU  - Wan H
AD  - School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - He, Yu
AU  - He Y
AD  - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Li, Xiaohong
AU  - Li X
AD  - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Yu, Li
AU  - Yu L
AD  - School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Jin, Weifeng
AU  - Jin W
AD  - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211118
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8637749
OTO - NOTNLM
OT  - ischemic stroke
OT  - long-term
OT  - recurrent stroke
OT  - secondary prevention
OT  - stroke risk factors
OT  - systematical analysis
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/07 06:00
MHDA- 2021/12/07 06:01
PMCR- 2021/11/18
CRDT- 2021/12/06 09:04
PHST- 2021/06/09 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/12/06 09:04 [entrez]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2021/12/07 06:01 [medline]
PHST- 2021/11/18 00:00 [pmc-release]
AID - 722975 [pii]
AID - 10.3389/fphar.2021.722975 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Nov 18;12:722975. doi: 10.3389/fphar.2021.722975. 
      eCollection 2021.